Discovery of selective aminothiazole aurora kinase inhibitors

ACS Chemical Biology

Volumn 3, Issue 3, 2008, Pages 180-192

  Andersen, Carsten B ^a   Wan, Yongqin ^a   Chang, Jae W ^c   Riggs, Blake ^d   Lee, Christian ^a   Liu, Yi ^a   Sessa, Fabio ^b   Villa, Fabrizio ^b   Kwiatkowski, Nicholas ^c   Suzuki, Melissa ^e   Nallan, Laxman ^a   Heald, Rebecca ^d   Musacchio, Andrea ^b   Gray, Nathanael S ^c  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INVITROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,5,6 TETRAHYDROPYRROLO[3,4 C]PYRAZOLE; 2 AMINOPHENYL; 2 AMINOPHENYL 5 BROMOTHIAZOLE DERIVATIVE; 2 PHENYLAMINOTHIAZOLE DERIVATIVE; 2,4 DIAMINOPYRIMIDINE DERIVATIVE; 5 CYANOAMINOTHIAZOLE; AMINOTHIAZOLE DERIVATIVE; AURORA KINASE INHIBITOR; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; HESPERADIN; HISTONE H3; INH 14; INH 29; INH 3M; INH 4; INH 45; INH 4B; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PYRAZOLOQUINAZOLINE; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; AMINE; AURORA KINASE; CYANIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; THIAZOLE DERIVATIVE;

ARTICLE; CELL CYCLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINESIS; ENDOREDUPLICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; XENOPUS LAEVIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION;

XENOPUS LAEVIS;

AMINES; ANIMALS; CYANATES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; XENOPUS LAEVIS;

EID: 42449137119     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb700200w     Document Type: Article

References (48)

1. Nigg, E. A. (2002) Centrosome aberrations: cause or consequence of cancer progression? Nat. Rev. Cancer 2, 815-825.
2. Glover, D. M. (2005) Polo kinase and progression through M phase in Drosophila: a perspective from the spindle poles, Oncogene 24, 230-237.
3. O'Connell, M. J., Krien, M. J., and Hunter, T. (2003) Never say never. The NIMA-related protein kinases in mitotic control, Trends Cell Biol. 13, 221-228.
4. Chan, C. S., and Botstein, D. (1993) Isolation and characterization of chromosome-gain and increase-in-ploidy mutants in yeast, Genetics 135, 677-691.
5. Glover, D. M., Leibowitz, M. H., McLean, D. A., and Parry, H. (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles, Cell 81, 95-105.
6. Tseng, T. C., Chen, S. H., Hsu, Y. P., and Tang, T. K. (1998) Protein kinase profile of sperm and eggs: cloning and characterization of two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and fly chromosome segregation regulators, DNA Cell Biol. 17, 823-833.
7. Kimura, M., Kotani, S., Hattori, T., Sumi, N., Yoshioka, T., Todokoro, K., and Okano, Y. (1997) Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1, J. Biol. Chem. 272, 13766-13771.
8. Kufer, T. A., Sillje, H. H., Korner, R., Gruss, O. J., Meraldi, P., and Nigg, E. A. (2002) Human TPX2 is required for targeting Aurora-A kinase to the spindle, J. Cell Biol. 158, 617-623.
9. Dutertre, S., Descamps, S., and Prigent, C. (2002) On the role of aurora-A in centrosome function, Oncogene 21, 6175-6183.
10. Terada, Y., Tatsuka, M., Suzuki, F., Yasuda, Y., Fujita, S., and Otsu, M. (1998) AIM-1: a mammalian midbody-associated protein required for cytokinesis, EMBO J. 17, 667-676.
11. Shannon, K. B., and Salmon, E. D. (2002) Chromosome dynamics: new light on Aurora B kinase function, Curr. Biol. 12, R458-R460.
12. Giet, R., McLean, D., Descamps, S., Lee, M. J., Raff, J. W., Prigent, C., and Glover, D. M. (2002) Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules, J. Cell Biol. 156, 437-451.
13. Sasai, K., Katayama, H., Stenoien, D. L., Fujii, S., Honda, R., Kimura, M., Okano, Y., Tatsuka, M., Suzuki, F., Nigg, E. A., Earnshaw, W. C., Brinkley, W. R., and Sen, S. (2004) Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells, Cell Motil. Cytoskeleton 59, 249-263.
14. Bischoff, J. R., Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginther, C., Chan, C. S., Novotny, M., Slamon, D. J., and Plowman, G. D. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers, EMBO J. 17, 3052-3065.
15. Zhou, H., Kuang, J., Zhong, L., Kuo, W. L., Gray, J. W., Sahin, A., Brinkley, B. R., and Sen, S. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation, Nat. Genet. 20, 189-193.
16. Ota, T., Suto, S., Katayama, H., Han, Z. B., Suzuki, F., Maeda, M., Tanino, M., Terada, Y., and Tatsuka, M. (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability, Cancer Res. 62, 5168-5177.
17. Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J. M., and Miller, K. M. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo, Nat Med 10, 262-7.
18. Ditchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., and Taylor, S. S. (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores, J. Cell Biol. 161, 267-280.
19. Hauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., and Peters, J. M. (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint, J. Cell Biol. 161, 281-294.
20. Fancelli, D., Berta, D., Bindi, S., Cameron, A., Cappella, P., Carpinelli, P., Catana, C., Forte, B., Giordano, P., Giorgini, M. L., Mantegani, S., Marsiglio, A., Meroni, M., Moll, J., Pittala, V., Roletto, F., Severino, D., Soncini, C., Storici, P., Tonani, R., Varasi, M., Vulpetti, A., and Vianello, P. (2005) Potent and selective Aurora inhibitors identifed by the expansion of a novel scaffold for protein kinase inhibition, J. Med. Chem. 48, 3080-3084.
21. Tari, L. W., Hoffman, I. D., Bensen, D. C., Hunter, M. J., Nix, J., Nelson, K. J., McRee, D. E., and Swanson, R. V. (2007) Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors, Bioorg. Med. Chem. Lett. 17, 688-691.
22. Mortlock, A. A., Foote, K. M., Heron, N. M., Jung, F. H., Pasquet, G., Lohmann, J. J., Warin, N., Renaud, F., De Savi, C., Roberts, N. J., Johnson, T., Dousson, C. B., Hill, G. B., Perkins, D., Hatter, G., Wilkinson, R. W., Wedge, S. R., Heaton, S. P., Odedra, R., Keen, N. J., Crafter, C., Brown, E., Thompson, K., Brightwell, S., Khatri, L., Brady, M. C., Kearney, S., McKillop, D., Rhead, S., Parry, T., and Green, S. (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase, J. Med. Chem. 50, 2213-2224.
23. Moriarty, K. J., Koblish, H. K., Garrabrant, T., Maisuria, J., Khalil, E., Ali, F., Petrounia, I. P., Crysler, C. S., Maroney, A. C., Johnson, D. L., and Galemmo, R. A., Jr (2006) The synthesis and SAR of 2-aminopyrrolo[ 2, 3-d]pyrimidines: a new class of Aurora-A kinase inhibitors, Bioorg. Med. Chem. Lett. 16, 5778-5783.
24. Cheetham, G. M., Knegtel, R. M., Coll, J. T., Renwick, S. B., Swenson, L., Weber, P., Lippke, J. A., and Austen, D. A. (2002) Crystal structure of aurora-2, an oncogenic serine/threonine kinase, J. Biol. Chem. 277, 42419-42422.
25. Melnick, J. S., Janes, J., Kim, S., Chang, J. Y., Sipes, D. G., Gunderson, D., Jarnes, L., Matzen, J. T., Garcia, M. E., Hood, T. L., Beigi, R., Xia, G., Harig, R. A., Asatryan, H., Yan, S. F., Zhou, Y., Gu, X. J., Saadat, A., Zhou, V., King, F. J., Shaw, C. M., Su, A. I., Downs, R., Gray, N. S., Schultz, P. G., Warmuth, M., and Caldwell, J. S. (2006) An efficient rapid system for profiling the cellular activities of molecular libraries, Proc. Natl. Acad. Sci. U.S.A. 103, 3153-3158.
26. Fabian, M. A., Biggs, W. H., 3rd, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors, Nat. Biotechnol. 23, 329-336.
27. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity, Nat. Biotechnol. 26, 127-132.
28. Sessa, F., Mapelli, M., Ciferri, C., Tarricone, C., Areces, L. B., Schneider, T. R., Stukenberg, P. T., and Musacchio, A. (2005) Mechanism of Aurora B activation by INCENP and inhibition by hesperadin, Mol. Cell 18, 379-391.
29. Hannak, E., and Heald, R. (2006) Investigating mitotic spindle assembly and function in vitro using Xenopus laevis egg extracts, Nat. Protoc. 1, 2305-2314.
30. Gadea, B. B., and Ruderman, J. V. (2006) Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin, Proc. Natl. Acad. Sci. U.S.A. 103, 4493-4498.
31. Liu, Q., and Ruderman, J. V. (2006) Aurora A, mitotic entry, and spindle bipolarity, Proc. Natl. Acad. Sci. U.S.A. 103, 5811-5816.
32. Warner, S. L., Bearss, D. J., Han, H., and Von Hoff, D. D. (2003) Targeting Aurora-2 kinase in cancer, Mol. Cancer Ther. 2, 589-595.
33. Weisberg, E., Boulton, C., Kelly, L. M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D. G., and Griffin, J. D. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412, Cancer Cell 1, 433-443.
34. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., and Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4-ylamino)-thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J. Med. Chem. 47, 6658-6661.
35. Sisko, J. T., Tucker, T. J., Bilodeau, M. T., Buser, C. A., Ciecko, P. A., Coll, K. E., Fernandes, C., Gibbs, J. B., Koester, T. J., Kohl, N., Lynch, J. J., Mao, X., McLoughlin, D., Miller-Stein, C. M., Rodman, L. D., Rickert, K. W., Sepp-Lorenzino, L., Shipman, J. M., Thomas, K. A., Wong, B. K., and Hartman, G. D. (2006) Potent 2-[(pyrimidin-4-yl)amine}-1, 3-thiazole-5 carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase, Bioorg. Med. Chem. Lett. 16, 1146-1150.
36. Kim, K. S., Kimball, S. D., Misra, R. N., Rawlins, D. B., Hunt, J. T., Xiao, H. Y., Lu, S., Qian, L., Han, W. C., Shan, W., Mitt, T., Cai, Z. W., Poss, M. A., Zhu, H., Sack, J. S., Tokarski, J. S., Chang, C. Y., Pavletich, N., Kamath, A., Humphreys, W. G., Marathe, P., Bursuker, I., Kellar, K. A., Roongta, U., Batorsky, R., Mulheron, J. G., Bol, D., Fairchild, C. R., Lee, F. Y., and Webster, K. R. (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities, J. Med. Chem. 45, 3905-3927.
37. Vulpetti, A., Casale, E., Roletto, F., Amici, R., Villa, M., and Pevarello, P. (2006) Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors, J. Mol. Graphics Modell. 24, 341-348.
38. Helal, C. J., Sanner, M. A., Cooper, C. B., Gant, T., Adam, M., Lucas, J. C., Kang, Z., Kupchinsky, S., Ahlijanian, M. K., Tate, B., Menniti, F. S., Kelly, K., and Peterson, M. (2004) Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease, Bioorg. Med. Chem. Lett. 14, 5521-5525.
39. Furet, P., Bold, G., Meyer, T., Roesel, J., and Guagnano, V. (2006) Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents, J. Med. Chem. 49, 4451-4454.
40. Borzilleri, R. M., Bhide, R. S., Barrish, J. C., D'Arienzo, C. J., Derbin, G. M., Fargnoli, J., Hunt, J. T., Jeyaseelan, R., Sr., Kamath, A., Kukral, D. W., Marathe, P., Mortillo, S., Qian, L., Tokarski, J. S., Wautlet, B. S., Zheng, X., and Lombardo, L. J. (2006) Discovery and evaluation of N-cyclopropyl- 2, 4-difluoro-5((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino) benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2, J. Med. Chem. 49, 3766-3769.
41. Liu, Y., and Gray, N. S. (2006) Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol. 2, 358-364.
42. Okram, B., Nagle, A., Adrian, F. J., Lee, C., Ren, P., Wang, X., Sim, T., Xie, Y., Wang, X., Xia, G., Spraggon, G., Warmuth, M., Liu, Y., and Gray, N. S. (2006) A general strategy for creating "inactive-conformation" abl inhibitors, Chem. Biol. 13, 779-786.
43. Otwinowski, Z., and Minor, W (1997) Processing of X-ray diffraction data collected in oscillation mode, Methods Enzymol. 276, 307-326.
44. Collaborative Computational Project Number 4. (1994) The CCP4 suite: programs for protein crystallography, Acta Crystallogr., Sect. D: Biol. Crystallogr. 50, 760-763.
45. Vagin, A., and Teplyakov, A. (1997) MOLREP: an automated program for molecular replacement, J. Appl. Crystallogr. 30, 1022-1025.
46. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics, Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132.
47. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method, Acta Crystallogr., Sect. D: Biol. Crystallogr. 53, 240-255.
48. Wignall, S. M., and Heald, R. (2001) Methods for the study of centrosome-independent spindle assembly in Xenopus extracts, Methods Cell Biol. 67, 241-256.